Lung Cancer

Newer treatments extend survival longer than traditional regimens

Published in Cancer Weekly, July 30th, 2002

Patients with advanced non-small cell lung cancer who are treated with regimens containing paclitaxel and carboplatin survive longer than patients treated with older cisplatin-based regimens or supportive care, a new study finds.

"While advanced lung cancer remains incurable, this study provides additional evidence that paclitaxel- and carboplatin-based regimens can prolong survival of patients with this disease," said John Hainsworth, MD, lead study author of a paper appearing in the Journal of Clinical Oncology and director of clinical research at the Sarah Cannon Cancer Center. "Survival beyond two years has been uncommon with previous treatments for advanced...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-07-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry